Here’s Who Just Picked Up Depomed Inc. (NASDAQ:DEPO) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Depomed Inc. (NASDAQ:DEPO) reported that Starboard Value LP has picked up 5,490,000 of common stock as of 2017-03-30.
The acquisition brings the aggregate amount owned by Starboard Value LP to a total of 5,490,000 representing a 8.8% stake in the company.
For those not familiar with the company, Depomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia. Its CAMBIA (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.
A glance at Depomed Inc. (NASDAQ:DEPO)’s key stats reveals a current market capitalization of 771.50 Million based on 62.10 Million shares outstanding and a price at last close of $12.82 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2013-05-10, Schoeneck picked up 25,000 at a purchase price of $5.11. This brings their total holding to 85,001 as of the date of the filing.
On the sell side, the most recent transaction saw Moretti unload 5,000 shares at a sale price of $20.84. This brings their total holding to 21,680.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Depomed Inc. (NASDAQ:DEPO) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Rosalind Advisors, Inc. Picked Zosano Pharma Corp (NASDAQ:ZSAN) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Zosano Pharma Corp (NASDAQ:ZSAN) reported that Rosalind Advisors, Inc. has picked up 2,083,100 of common stock as of 2017-03-29.
The acquisition brings the aggregate amount owned by Rosalind Advisors, Inc. to a total of 2,083,100 representing a 5.5% stake in the company.
For those not familiar with the company, Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.
A glance at Zosano Pharma Corp (NASDAQ:ZSAN)’s key stats reveals a current market capitalization of 62.47 Million based on 33.82 Million shares outstanding and a price at last close of $1.88 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-08-19, Erbez picked up 47,750 at a purchase price of $1.32. This brings their total holding to 47,750 as of the date of the filing.
On the sell side, the most recent transaction saw Barrett unload 1,099,996 shares at a sale price of $2.01. This brings their total holding to 952,809.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Zosano Pharma Corp (NASDAQ:ZSAN) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Sacks Bradley J. Picked Up Uluru Inc. (OTCMKTS:ULUR) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Uluru Inc. (OTCMKTS:ULUR) reported that Sacks Bradley J. has picked up 552,960 of common stock as of 2017-03-02.
The acquisition brings the aggregate amount owned by Sacks Bradley J. to a total of 552,960 representing a 0.9% stake in the company.
For those not familiar with the company, ULURU Inc. is a specialty pharmaceutical company focused on developing and commercializing a range of wound care and muco-adhesive film products based on its Nanoflex and OraDisc technologies for patients, healthcare professionals and healthcare payers. The Company operates through the research, development and commercialization of pharmaceutical products segment. Utilizing its technologies, three of its products have been approved for marketing in various global markets. Altrazeal Transforming Powder Dressing is based on its Nanoflex technology, which changes the way healthcare providers approach their treatment of wounds. The product is indicated for both exuding acute wounds, such as donor sites, non-healing surgical wounds, and trauma and for chronic wounds, such as venous leg ulcers, diabetic foot ulcers and pressure ulcers. Aphthasol is a drug approved for the treatment of canker sores. OraDisc is developed as an improved drug delivery system for the treatment of canker sores.
A glance at Uluru Inc. (OTCMKTS:ULUR)’s key stats reveals a current market capitalization of 4.03 million based on 62.97 Million shares outstanding and a price at last close of $0.0711 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-03-29, Wallberg picked up 701,262 at a purchase price of $0.07. This brings their total holding to 825,519 as of the date of the filing.
On the sell side, the most recent transaction saw Oss unload 3,400,000 shares at a sale price of $0.16. This brings their total holding to 8,061,522.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Uluru Inc. (OTCMKTS:ULUR) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Uluru Inc. (OTCMKTS:ULUR) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Uluru Inc. (OTCMKTS:ULUR) reported that Sacks Michael Ivan has picked up 30,050,490 of common stock as of 2017-03-02.
The acquisition brings the aggregate amount owned by Sacks Michael Ivan to a total of 30,050,490 representing a 39.0% stake in the company.
For those not familiar with the company, ULURU Inc. is a specialty pharmaceutical company focused on developing and commercializing a range of wound care and muco-adhesive film products based on its Nanoflex and OraDisc technologies for patients, healthcare professionals and healthcare payers. The Company operates through the research, development and commercialization of pharmaceutical products segment. Utilizing its technologies, three of its products have been approved for marketing in various global markets. Altrazeal Transforming Powder Dressing is based on its Nanoflex technology, which changes the way healthcare providers approach their treatment of wounds. The product is indicated for both exuding acute wounds, such as donor sites, non-healing surgical wounds, and trauma and for chronic wounds, such as venous leg ulcers, diabetic foot ulcers and pressure ulcers. Aphthasol is a drug approved for the treatment of canker sores. OraDisc is developed as an improved drug delivery system for the treatment of canker sores.
A glance at Uluru Inc. (OTCMKTS:ULUR)’s key stats reveals a current market capitalization of 4.03 million based on 62.97 Million shares outstanding and a price at last close of $0.0711 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-03-29, Wallberg picked up 701,262 at a purchase price of $0.07. This brings their total holding to 825,519 as of the date of the filing.
On the sell side, the most recent transaction saw Oss unload 3,400,000 shares at a sale price of $0.16. This brings their total holding to 8,061,522.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Uluru Inc. (OTCMKTS:ULUR) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Just Picked Up Egalet Corp. (NASDAQ:EGLT) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Egalet Corp. (NASDAQ:EGLT) reported that Broadfin Capital has picked up 1,228,751 of common stock as of 2017-02-13.
The acquisition brings the aggregate amount owned by Broadfin Capital to a total of 1,228,751 representing a 4.75% stake in the company.
For those not familiar with the company, Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company’s product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company’s product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company’s product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.
A glance at Egalet Corp. (NASDAQ:EGLT)’s key stats reveals a current market capitalization of 116.13 million based on 25.19 million shares outstanding and a price at last close of $4.63 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2014-02-11, Index picked up 266,771 at a purchase price of $12.00. This brings their total holding to 1,007,033 as of the date of the filing.
On the sell side, the most recent transaction saw Dayno unload 536 shares at a sale price of $7.75. This brings their total holding to 18,748.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Egalet Corp. (NASDAQ:EGLT) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.